Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell EngagersBusiness Wire • 09/09/24
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • 08/22/24
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?Zacks Investment Research • 08/06/24
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/01/24
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline OpportunitiesBusiness Wire • 08/01/24
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell EngagersBusiness Wire • 08/01/24
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024Business Wire • 07/18/24
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And HepatitisSeeking Alpha • 07/17/24
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta InfectionBusiness Wire • 06/26/24
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentBusiness Wire • 06/05/24
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 05/29/24
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical OfficerBusiness Wire • 05/29/24
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024Business Wire • 05/22/24
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024Business Wire • 05/21/24
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 StudiesPRNewsWire • 05/13/24
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a BetZacks Investment Research • 05/07/24
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/02/24